Europe Diabetes Drugs Market: Market Size & Forecast 2026

Europe represents one of the world's largest regional markets for diabetes pharmaceuticals, with a 2025 valuation of $15.44 billion. The broader European diabetes management ecosystem, including care devices, was valued at $8.53 billion in 2025 and is expected to nearly double to $15.11 billion by 2030. Germany alone accounts for approximately $12 billion of the regional drugs market, making it the dominant national market within Europe.

• •European diabetes drugs market size: $15.44 billion (2025) with a projected $21.79 billion by 2031
• •Insulin segment growing at approximately 3% CAGR through 2030
• •Germany is the largest European national market at $12.0 billion in 2025

The market expansion is supported by increasing prevalence of both type 1 and type 2 diabetes across European populations, influenced by lifestyle factors and rising obesity rates. Healthcare infrastructure investments and government initiatives to improve diabetes care access have accelerated adoption of advanced treatment options. Additionally, the introduction and uptake of novel drug classes, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have broadened therapeutic options and driven segment growth.

• •Rising diabetes incidence across Europe, supported by WHO epidemiological data
• •Government healthcare funding and diabetes care programs expanding treatment access
• •Growing adoption of newer drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors

The European market encompasses multiple drug categories including insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and other oral and injectable antidiabetic agents. Germany dominates the regional landscape with a 2025 market size of $12.0 billion, while the UK, France, Italy, and Spain represent other key national markets. The insulin sub-market is projected to grow at a 3% CAGR from 2025 to 2030, while the overall drug market is expected to expand at a faster pace of 5.89% annually.

• •Key drug categories: insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors
• •Germany leads European national markets at $12.0 billion (2025)
• •Insulin segment CAGR: ~3% (2025-2030); overall drugs market CAGR: ~5.89% through 2031

What are the recent trends and outlook?

The market is anticipated to sustain robust growth through 2031, driven by continued demographic shifts and an aging patient population across Europe. GLP-1 receptor agonists are expected to remain a primary growth engine as clinical evidence expands their use and manufacturing scales improve supply. The broader European diabetes sector, including drugs and care devices, is on track to represent a combined market opportunity exceeding $37 billion by the early 2030s.

• •Projected European diabetes drugs market: $21.79 billion by 2031
• •GLP-1 receptor agonist class expected to remain a key growth driver
• •Combined drugs and devices market projected to exceed $37 billion by the early 2030s